MBX Biosciences Net Income Over Time
| MBX Stock | 39.22 0.15 0.38% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out MBX Biosciences Performance and MBX Biosciences Correlation. Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of MBX Biosciences. Expected growth trajectory for MBX significantly influences the price investors are willing to assign. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive MBX Biosciences assessment requires weighing all these inputs, though not all factors influence outcomes equally.
MBX Biosciences Common's market price often diverges from its book value, the accounting figure shown on MBX's balance sheet. Smart investors calculate MBX Biosciences' intrinsic value - its true economic worth - which may differ significantly from both market price and book value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Since MBX Biosciences' trading price responds to investor sentiment, macroeconomic conditions, and market psychology, it can swing far from fundamental value.
Understanding that MBX Biosciences' value differs from its trading price is crucial, as each reflects different aspects of the company. Evaluating whether MBX Biosciences represents a sound investment requires analyzing earnings trends, revenue growth, technical signals, industry dynamics, and expert forecasts. However, MBX Biosciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Cross Equities Net Income Analysis
Compare MBX Biosciences Common and related stocks such as MeiraGTx Holdings PLC, Replimune Group, and ArriVent BioPharma Common Net Income Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| MGTX | (19.5 M) | (19.5 M) | (19.5 M) | (19.5 M) | (19.5 M) | (19.5 M) | (19.5 M) | (31 M) | (82.9 M) | (54.7 M) | (58 M) | (79.6 M) | (129.6 M) | (84 M) | (147.8 M) | (133 M) | (126.4 M) |
| REPL | (7.7 M) | (7.7 M) | (7.7 M) | (7.7 M) | (7.7 M) | (7.7 M) | (7.7 M) | (19.7 M) | (30.8 M) | (52.6 M) | (80.9 M) | (118 M) | (174.3 M) | (215.8 M) | (247.3 M) | (222.6 M) | (211.4 M) |
| AVBP | (51.6 M) | (51.6 M) | (51.6 M) | (51.6 M) | (51.6 M) | (51.6 M) | (51.6 M) | (51.6 M) | (51.6 M) | (51.6 M) | (51.6 M) | (36.9 M) | (69.3 M) | (80.5 M) | (80.5 M) | (72.4 M) | (76.1 M) |
| DNA | (119.3 M) | (119.3 M) | (119.3 M) | (119.3 M) | (119.3 M) | (119.3 M) | (119.3 M) | (119.3 M) | (119.3 M) | (119.3 M) | (126.6 M) | (1.8 B) | (2.1 B) | (892.9 M) | (547 M) | (492.3 M) | (516.9 M) |
| IOVA | (57.1 K) | (25.7 M) | (3.3 M) | (25.4 M) | (12 M) | (27.7 M) | (52.9 M) | (92.1 M) | (123.6 M) | (187.1 M) | (259.6 M) | (327.8 M) | (389.9 M) | (444 M) | (372.2 M) | (335 M) | (318.2 M) |
| MLTX | (90.8 K) | (90.8 K) | (90.8 K) | (90.8 K) | (90.8 K) | (90.8 K) | (90.8 K) | (90.8 K) | (90.8 K) | (90.8 K) | (90.8 K) | (4.5 M) | (64.5 M) | (36 M) | (118.9 M) | (107 M) | (101.7 M) |
| ATXS | (15.7 K) | (15.7 K) | (15.7 K) | (18.1 M) | (21.9 M) | (32.6 M) | (36.1 M) | (27.4 M) | (25.9 M) | (26.3 M) | (37.1 M) | (194.9 M) | (50.2 M) | (72.9 M) | (94.3 M) | (84.8 M) | (80.6 M) |
| ERAS | (12 M) | (12 M) | (12 M) | (12 M) | (12 M) | (12 M) | (12 M) | (12 M) | (12 M) | (12 M) | (101.7 M) | (122.8 M) | (242.8 M) | (125 M) | (161.7 M) | (145.5 M) | (152.8 M) |
| RGNX | (5.4 M) | (5.4 M) | (5.4 M) | (5.4 M) | (4 M) | (22.8 M) | (63 M) | (73.2 M) | 99.9 M | (94.7 M) | (111.2 M) | 127.8 M | (280.3 M) | (263.5 M) | (227.1 M) | (204.4 M) | (194.2 M) |
| VSTM | (786 K) | (13.7 M) | (32 M) | (41.2 M) | (53.4 M) | (57.9 M) | (36.4 M) | (67.8 M) | (72.4 M) | (149.2 M) | (67.7 M) | (71.2 M) | (73.8 M) | (87.4 M) | (130.6 M) | (117.6 M) | (111.7 M) |
MBX Biosciences Common and related stocks such as MeiraGTx Holdings PLC, Replimune Group, and ArriVent BioPharma Common Net Income description
Net income is one of the most important fundamental items in finance. It plays a large role in MBX Biosciences Common financial statement analysis. It represents the amount of money remaining after all of MBX Biosciences Common operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue.My Equities
My Current Equities and Potential Positions
| MBX Biosciences Common | MBX |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Business Address | 11711 North Meridian |
| Exchange | NASDAQ Exchange |
null 39.22
Additional Tools for MBX Stock Analysis
When running MBX Biosciences' price analysis, check to measure MBX Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy MBX Biosciences is operating at the current time. Most of MBX Biosciences' value examination focuses on studying past and present price action to predict the probability of MBX Biosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move MBX Biosciences' price. Additionally, you may evaluate how the addition of MBX Biosciences to your portfolios can decrease your overall portfolio volatility.